Table 2. Correlation between baseline CTCs counts and clinical parameters in 46 mCRC patients receiving first-line chemotherapy.
| Characteristic | Number | CTCs detection | χ2e | P | |
|---|---|---|---|---|---|
| Positive (%) | Negative (%) | ||||
| Age (year) | 4.330 | 0.037 | |||
| <63 | 22 | 7 [32] | 15 [68] | ||
| ≥63 | 24 | 15 [63] | 9 [37] | ||
| Gender | 0.046 | 0.829 | |||
| Male | 30 | 14 [47] | 16 [53] | ||
| Female | 16 | 8 [50] | 8 [50] | ||
| Tumor localization | |||||
| Colon | 21 | 10 [48] | 11 [52] | 0.001 | 0.979 |
| Rectum | 25 | 12 [48] | 13 [52] | ||
| Metastasis sites | 0.163 | 0.686 | |||
| Liver | 30 | 15 [50] | 15 [50] | ||
| Others | 16 | 7 [44] | 9 [56] | ||
| Chemotherapy regimens | 1.564 | 0.458 | |||
| FOLFORI | 18 | 7 [39] | 11 [61] | ||
| FOLFOX | 13 | 8 [62] | 5 [38] | ||
| XELOX | 15 | 7 [47] | 8 [53] | ||
| PLR value | |||||
| Low PLR groupa | 22 | 6 [27] | 16 [73] | 7.139 | 0.008 |
| High PLR groupb | 24 | 16 [67] | 8 [33] | ||
| NLR value | 4.506 | 0.034 | |||
| Low NLR groupc | 20 | 6 [30] | 14 [70] | ||
| High NLR groupd | 26 | 16 [62] | 10 [38] | ||
a, Low PLR group, PLR <117.81; b, High PLR group, PLR ≥117.81; c, Low NLR group, NLR <2.02; d, High NLR group, NLR≥2.02; e, Chi-square test. PLR, platelet-lymphocyte ratio; NLR, neutrophil-lymphocyte ratio; CTCs, circulating tumor cells.